CervoMed's neflamapimod Phase 2a nfvPPA data accepted as late-breaking oral at ISFTD 2026

CervoMed Inc.

Phase 2a trial of neflamapimod in nfvPPA completed enrollment with 25 participants.
12-week biomarker data from first 8 participants accepted as late-breaking oral at ISFTD 2026 (Oct 8-11, Philadelphia).
Presentation will highlight NfL and GFAP biomarker results from at least 22 participants.
nfvPPA has no approved treatments in US or EU; trial conducted at US and UK academic centers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.